This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

RNA Leaders APAC
New Data, Case Studies & Partners
October 15-16, 2025Marina Bay Sands, Singapore
Book Now
Menu
Book
Key Sessions
Pall Thordarson
Scaling & Manufacturing Sustainable and Personalised RNA Therapeutics & Vaccines
UNSW
keyboard_arrow_right

Day 2 - UTC+08:00

keyboard_arrow_leftSearch & Filter
search
Day 2 - UTC+08:00
search
7:45am - 8:50am
Registration
Showing 1 of 1 Streams
8:50am - 9:00am
RNA Leaders Welcome
9:00am - 9:45am
Investment, Partnering & External Innovation – Catalyzing International Big Pharma & Investment with APAC Partnerships for the Next Wave of RNA Therapies
  • Jenny Yang - Head of External Innovation Asia-Pacific, Novo Nordisk
  • Soyoung Park - General Partner, 1004 Venture Partners
  • Eddie Li - Director, Genetic Medicine, Eli Lilly
9:45am - 10:30am
Scaling & Manufacturing Sustainable and Personalised RNA Therapeutics & Vaccines
  • Pall Thordarson - Director of the UNSW RNA Institute, UNSW
  • Tim Mercer - Director, The University of Queensland
10:30am - 11:30am
Networking Power Hour
Showing 1 of 1 Streams
11:30am - 12:00pm
Next-Generation mRNA Therapies
  • Overview of mRNA and its traditional role in vaccine
  • Overview of mRNA applications beyond vaccines
  • 2-3 examples of alternative mRNA use
  • Current challenges in the application of mRNA beyond vaccines
  • Archa Fox - Director, Australian Centre for RNA Therapeutics in Cancer, RNA Innovation Foundry
12:00pm - 12:30pm
Logic-Gated mRNA: Precision On-Off Switches for Cell-Type-Specific Therapies
  • Sophia Lugo - CEO, Radar Therapeutics
12:30pm - 1:00pm
Synthetic, enzymatically produced GMP grade DNA for production of mRNA Therapies and Vaccines
  • 4basebio is a GMP certified manufacturer of synthetic DNA, with a mission to enable next generation cell and gene therapies and vaccines with its technologies and solutions
  • 4basebio design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies
  • 4basebio's clinically validated opDNA™ construct is ideally suited for mRNA production, with no need for enzymatic linearisation and facilitating dose reductions and increased purity as compared to plasmid DNA
  • opDNA™ achieves significantly higher mRNA yields, comparable proinflammatory cytokine/chemokine responses, homogenous polyA tails of up to 180As, and equivalent gene expression as compared to plasmid derived templates, with no bacterial sequences present
  • Amy Walker - COO & EVP of Research and Business Development, 4Basebio
1:00pm - 2:15pm
Lunch
Showing 1 of 1 Streams
2:15pm - 2:45pm
Thiomorpholino Oligonucleotide Biological Research
  • Marvin Caruthers, PhD - Distinguished Professor, Biochemistry, University of Colorado
2:45pm - 3:15pm
Chemistry, Design and Dynamics of Novel Splice Switching Antisense Oligonucleotides
  • Rakesh Naduvile Veedu - Professor & Head Precision Nucleic Acid Therapeutics Group Co-Founder, ProGenis Pharmaceuticals (RNA therapeutics development) Founder, SynGenis Pty Ltd (RNA Manufacturing), Murdoch University
3:15pm - 3:45pm
Development of exon skipping technology for the treatment of Duchenne muscular dystrophy
3:45pm - 4:15pm
Afternoon Break
Showing 1 of 1 Streams
4:15pm - 5:15pm
RNA Leaders CEO Forum
5:15pm - 5:30pm
Closing Remarks
5:30pm - 5:35pm
Close of Congress
Day 1
Filter
Streams
Formats
Choose Day